Nvidia-backed Iambic Therapeutics Climbs in Stock Market Debut

Key Facts

1Nvidia-backed drug discovery firm Iambic Therapeutics saw its shares climb during its trading debut.

2The company's initial public offering was priced at $16.00 per share.

Nvidia-backed drug discovery firm Iambic Therapeutics saw its shares climb during its trading debut. Seeking Alpha reported that the company's initial public offering was priced at $16.00 per share prior to the start of trading.

The positive price reaction reflects investor interest in AI-driven healthcare and Nvidia's strategic investment portfolio. NVDA was trading at $217.26 on October 15, 2026, while peer semiconductor stocks AMD and INTC closed at $570.82 and $98.12 respectively on October 14, 2026.